Electrophysiological and Clinical Effects of Walking Downhill in Stroke Patients

Sponsor
Marmara University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05833295
Collaborator
(none)
21
1
3
12
1.7

Study Details

Study Description

Brief Summary

investigation of the effects of walking for 20 minutes on the acute H/M ratio on flat ground, downhill slopes at -7.5 degrees and -15 degrees in patients who have had a stroke, have spasticity and are ambulatory.

At the same time, the aim of the study is to obtain the clinical effectiveness of this walking pattern and control of the H/M ratio by checking the H/M ratio again after 5 sessions and 20 minutes of walking for the patients participating in the study.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Downhill walking
  • Procedure: Walking on flat ground
N/A

Detailed Description

Participants will wear a seat belt connected to an overhead support and will walk on a treadmill with a dual-band instrument at a sampling frequency of 2000 Hz. The seat belt will only serve as a safety mechanism in case of a fall and will not support any body weight while walking. Each participant will walk for 20 minutes under one of 3 slope conditions; treadmill walking on 0° flat ground, , downhill walking with treadmill on -7.5° slope and downhill walking with treadmill on -15° slope.

First, by asking the participants to walk at their comfortable speed for straight walking on the treadmill with tools, the walking speed will be determined and carried out at the specified speeds. All self-selected walking speeds will be determined in two 30-second trials. During the 20-minute walk for each condition, if the participant needs to slow down, the speed of the treadmill will be reduced to adapt to this, and the average walking speed during the 20-minute walking session will be reported. Pulse and blood pressure will be monitored before, during and after the walk.

All participants will be evaluated with modified asworth scale, modified tardeu scale, 2 minute walking test, modified rankin scale, timed get up and walk test, fatigue impact scale, stroke impact scale, berg balance scale, fugl meyer assessment scale before treatment.

Patients will be randomized into 3 groups. Then, the H / M ratio will be looked at in all 3 groups. After the first walking session, the H / M ratio will be repeated. after completing the 5-session walking program, clinical and electrophysiological tests will be repeated.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
21 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Outcomes Assessor)
Masking Description:
Patients will be randomized into 3 groups. Clinical and electrophysiological tests before and after walking sessions will be performed by an unannounced researcher.
Primary Purpose:
Treatment
Official Title:
Electrophysiological and Clinical Effects of Walking Downhill in Stroke Patients
Anticipated Study Start Date :
Apr 24, 2023
Anticipated Primary Completion Date :
May 24, 2023
Anticipated Study Completion Date :
Apr 24, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Walking on flat ground

Patients will walk for 20 minutes at a 0% slope.

Procedure: Walking on flat ground
Change in the H/M ratio after a Walking on flat ground

Experimental: -%7.5 Downhill walking

They will walk downhill for 20 minutes at a -(negative)7.5% gradient.

Procedure: Downhill walking
Change in the H/M ratio after a downhill walk.

Experimental: -%15 Downhill walking

They will walk downhill for 20 minutes at a -(negative)15% gradient.

Procedure: Downhill walking
Change in the H/M ratio after a downhill walk.

Outcome Measures

Primary Outcome Measures

  1. the change in the H/M ratio after a 20-minute walk. [Day 0: Before the walk]

    Each participant will be evaluated for changes in the H/M ratio with an EMG device before the walk, on the 1st day of the walk, and on the 5th day of the walk.

  2. the change in the H/M ratio after a 20-minute walk. [Day 1: First day of 20-minute walk]

    Each participant will be evaluated for changes in the H/M ratio with an EMG device before the walk, on the 1st day of the walk, and on the 5th day of the walk.

  3. the change in the H/M ratio after a 20-minute walk. [Day 5: The fifth day of the 20-minute walk]

    Each participant will be evaluated for changes in the H/M ratio with an EMG device before the walk, on the 1st day of the walk, and on the 5th day of the walk.

Secondary Outcome Measures

  1. Modified Asworth Scale [Day 0: Before the walk]

    Modified Asworth Scale is a spasticity assessment test. It contains 4 points in total. As the score increases, the degree of spasticity increases.

  2. Modified Asworth Scale [Day 5: The fifth day of the 20-minute walk]

    Modified Asworth Scale is a spasticity assessment test. It contains 4 points in total. As the score increases, the degree of spasticity increases.

  3. Modified Tardeu Scale [Day 0: Before the walk]

    Modified Tardeu Scale is a spasticity assessment test. It contains 5 points in total. As the score increases, the degree of spasticity increases.

  4. Modified Tardeu Scale [Day 5: The fifth day of the 20-minute walk]

    Modified Tardeu Scale is a spasticity assessment test. It contains 5 points in total. As the score increases, the degree of spasticity increases.

  5. Walking test [Day 0: Before the walk]

    2 minute walking test

  6. Walking test [Day 5: The fifth day of the 20-minute walk]

    2 minute walking test

  7. Walking capacity [Day 0: Before the walk]

    Timed Get Up and Walk Test

  8. Walking capacity [Day 5: The fifth day of the 20-minute walk]

    Timed Get Up and Walk Test

  9. The Fatigue Effect Scale [Day 0: Before the walk]

    The fatigue effect scale consists of 9 questions. Each question gets points between 0 and 7. The total score is divided by the number of questions. If the result is greater than 6.1, it is defined as chronic fatigue.

  10. Fatigue [Day 5: The fifth day of the 20-minute walk]

    The fatigue effect scale consists of 9 questions. Each question gets points between 0 and 7. The total score is divided by the number of questions. If the result is greater than 6.1, it is defined as chronic fatigue.

  11. Stroke impact scale [Day 0: Before the walk]

    Stroke Impact Scale; patients' quality of life after stroke to assess their perception by themselves or their caregivers This scale consists of 8 subsections and 59 questions. each one question is a 5-point Likert scale of difficulty experienced in the past week. It is scored by evaluation on the scale. each section The score ranges from 0 to 100. In addition, the stroke impact scale has 8 subsections. 0-100 point visual analog of the perception of recovery after stroke. scale (0: No improvement, 100: Full recovery)

  12. Stroke impact scale [Day 5: The fifth day of the 20-minute walk]

    Stroke Impact Scale; patients' quality of life after stroke to assess their perception by themselves or their caregivers This scale consists of 8 subsections and 59 questions. each one question is a 5-point Likert scale of difficulty experienced in the past week. It is scored by evaluation on the scale. each section The score ranges from 0 to 100. In addition, the stroke impact scale has 8 subsections. 0-100 point visual analog of the perception of recovery after stroke. scale (0: No improvement, 100: Full recovery)

  13. Berg Equilibrium Scale [Day 0: Before the walk]

    It is a scale that includes 14 instructions and is scored between 0-4 by observing the patient's performance for each instruction. While 0 points are given when the patient cannot do the activity at all, 4 points are given when the patient completes the activity independently. The highest score is 56, with 0-20 points indicating balance disorder, 21 40 points indicating an acceptable balance, 41-56 points indicating a good balance. It takes between 10 and 20 minutes to complete the scale. It is a scale that includes 14 instructions and is scored between 0-4 by observing the patient's performance for each instruction. While 0 points are given when the patient cannot do the activity at all, 4 points are given when the patient completes the activity independently. The highest score is 56, with 0-20 points indicating balance disorder, 21 40 points indicating an acceptable balance, 41-56 points indicating a good balance. It takes between 10 and 20 minutes to complete the scale.

  14. Berg Equilibrium Scale [Day 5: The fifth day of the 20-minute walk]

    It is a scale that includes 14 instructions and is scored between 0-4 by observing the patient's performance for each instruction. While 0 points are given when the patient cannot do the activity at all, 4 points are given when the patient completes the activity independently. The highest score is 56, with 0-20 points indicating balance disorder, 21 40 points indicating an acceptable balance, 41-56 points indicating a good balance. It takes between 10 and 20 minutes to complete the scale.

  15. Fugl-Meyer Assessment Scale [Day 0: Before the walk]

    The full version of FMRS assesses five domains: motor function, balance, sensory function, range of motion (ROM) and joint pain. In the full version of the scale, when all subscales (sensory function 24 points, balance 14 points, ROM 44 points, joint pain 44 points and motor-coordination 100 points) are added, the maximum total score is 226. The motor-coordination subscale is a maximum of 66 points for the upper extremity and a maximum of 34 points for the lower extremities. Higher scores indicate better motor recovery. Each item is scored with a 3-point ordinal scale (0: unable at all, 1: partially able, 2: fully able). When items related to coordination and speed are not included in the evaluation in the lower extremity motor-coordination subscale, it is specified as the lower extremity motor subscale and its maximum score is evaluated out of 28.

  16. Fugl-Meyer Assessment Scale [Day 5: The fifth day of the 20-minute walk]

    The full version of FMRS assesses five domains: motor function, balance, sensory function, range of motion (ROM) and joint pain. In the full version of the scale, when all subscales (sensory function 24 points, balance 14 points, ROM 44 points, joint pain 44 points and motor-coordination 100 points) are added, the maximum total score is 226. The motor-coordination subscale is a maximum of 66 points for the upper extremity and a maximum of 34 points for the lower extremities. Higher scores indicate better motor recovery. Each item is scored with a 3-point ordinal scale (0: unable at all, 1: partially able, 2: fully able). When items related to coordination and speed are not included in the evaluation in the lower extremity motor-coordination subscale, it is specified as the lower extremity motor subscale and its maximum score is evaluated out of 28.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 65 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:

patients diagnosed with stroke between the ages of 18 and 65 Dec

Exclusion Criteria:
  • Other neurological disorders,

  • Expressive or receptive aphasias,

  • Severe heart disease,

  • A history of poorly controlled diabetes,

  • Active cancer,

  • Those who have been injected with botilinum toxin in the last 3 months,

  • Orthopedic conditions affecting the legs, a history of hip or knee replacement,

  • Serious simultaneous medical problems, such as peripheral nerve damage

  • Inability to comprehend verbal instructions

Contacts and Locations

Locations

Site City State Country Postal Code
1 Mamara Üniversitesi Tıp Fakültesi Istanbul Turkey 34000

Sponsors and Collaborators

  • Marmara University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Marmara University
ClinicalTrials.gov Identifier:
NCT05833295
Other Study ID Numbers:
  • MAR.FTR.ST
First Posted:
Apr 27, 2023
Last Update Posted:
Apr 27, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 27, 2023